ATE465253T1 - Glykoformen von faktor vii - Google Patents

Glykoformen von faktor vii

Info

Publication number
ATE465253T1
ATE465253T1 AT01971734T AT01971734T ATE465253T1 AT E465253 T1 ATE465253 T1 AT E465253T1 AT 01971734 T AT01971734 T AT 01971734T AT 01971734 T AT01971734 T AT 01971734T AT E465253 T1 ATE465253 T1 AT E465253T1
Authority
AT
Austria
Prior art keywords
factor vii
glycoforms
asparagine
compositions
relates
Prior art date
Application number
AT01971734T
Other languages
English (en)
Inventor
Hans Pingel
Niels Klausen
Original Assignee
Novo Nordisk Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27439823&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE465253(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk Healthcare Ag filed Critical Novo Nordisk Healthcare Ag
Application granted granted Critical
Publication of ATE465253T1 publication Critical patent/ATE465253T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01971734T 2000-10-02 2001-10-02 Glykoformen von faktor vii ATE465253T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200001456 2000-10-02
DKPA200100262 2001-02-16
DKPA200100430 2001-03-14
DKPA200100751 2001-05-14
PCT/DK2001/000633 WO2002029025A2 (en) 2000-10-02 2001-10-02 Factor vii glycoforms

Publications (1)

Publication Number Publication Date
ATE465253T1 true ATE465253T1 (de) 2010-05-15

Family

ID=27439823

Family Applications (2)

Application Number Title Priority Date Filing Date
AT01971734T ATE465253T1 (de) 2000-10-02 2001-10-02 Glykoformen von faktor vii
AT01976037T ATE425254T1 (de) 2000-10-02 2001-10-02 Verfahren zur herstellung vitamin-k-abhängiger proteine

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT01976037T ATE425254T1 (de) 2000-10-02 2001-10-02 Verfahren zur herstellung vitamin-k-abhängiger proteine

Country Status (18)

Country Link
US (6) US6903069B2 (de)
EP (6) EP1325147A2 (de)
JP (4) JP2004510439A (de)
KR (2) KR100880624B1 (de)
CN (3) CN1481438A (de)
AT (2) ATE465253T1 (de)
AU (5) AU9165201A (de)
BR (2) BR0114373A (de)
CA (2) CA2422216C (de)
CZ (1) CZ2003718A3 (de)
DE (2) DE60137950D1 (de)
ES (2) ES2323761T3 (de)
HU (2) HUP0301267A3 (de)
IL (2) IL154879A0 (de)
MX (1) MXPA03002853A (de)
NO (1) NO20031471L (de)
PL (2) PL361017A1 (de)
WO (4) WO2002029025A2 (de)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7786070B2 (en) 1997-09-10 2010-08-31 Novo Nordisk Healthcare A/G Subcutaneous administration of coagulation factor VII
US20050032690A1 (en) * 1997-09-10 2005-02-10 Rojkjaer Lisa Payne Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia
US7247708B2 (en) 1997-10-23 2007-07-24 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US6747003B1 (en) * 1997-10-23 2004-06-08 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
ES2292682T3 (es) 1998-05-06 2008-03-16 Genentech, Inc. Purificacion de anticuerpos mediante cromatografia de intercambio ionico.
PL204285B1 (pl) * 2000-02-11 2009-12-31 Bayer Healthcare Llc Koniugat polipeptydowy, polipeptyd, sekwencja nukleotydowa, wektor ekspresyjny, komórka gospodarz, sposób wytwarzania koniugatu polipeptydowego, środek farmaceutyczny i zastosowanie koniugatu polipeptydowego
US7812132B2 (en) 2000-04-28 2010-10-12 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US7220837B1 (en) 2000-04-28 2007-05-22 Regents Of The University Of Minnesota Modified vitamin K-dependent polypeptides
US20030211094A1 (en) 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
US20030040480A1 (en) * 2001-07-20 2003-02-27 Rasmus Rojkjaer Pharmaceutical composition comprising factor VII polypeptides and factor XI polypeptides
HUP0402158A2 (hu) 2001-10-02 2005-01-28 Novo Nordisk Health Care Ag Rekombináns fehérjék előállítási eljárása eukarióta sejtekben
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
KR20040065278A (ko) * 2001-12-21 2004-07-21 노보 노르디스크 에이/에스 변경된 인자 ⅶ 폴리펩티드의 액체 조성물
ES2325653T3 (es) 2001-12-21 2009-09-11 Novo Nordisk Health Care Ag Composicion liquida de polipeptidos del factor vii.
BR0309576A (pt) * 2002-04-30 2005-02-09 Maxygen Holdings Ltd Variante de polipeptìdeo do fator vii (fvii) ou fator viia (fviia), sequência de nucleotìdeo, vetor de expressão, célula hospedeira, composição farmacêutica, uso de uma variante, e, método para tratar um mamìfero que tenha uma doença ou um distúrbio em que a formação de coágulo é desejável
US20040009918A1 (en) * 2002-05-03 2004-01-15 Hanne Nedergaard Stabilised solid compositions of modified factor VII
ATE503498T1 (de) * 2002-06-21 2011-04-15 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
CA2490342C (en) 2002-06-21 2015-06-16 Novo Nordisk A/S Stabilised solid compositions of factor vii polypeptides
CA2502162C (en) * 2002-09-30 2014-04-15 Bayer Healthcare Llc Fvii or fviia variants having increased clotting activity
CA2518327A1 (en) * 2003-03-18 2004-09-30 Novo Nordisk Health Care Ag Liquid, aqueous, pharmaceutical compositions of factor vii polypeptides
JP4885707B2 (ja) * 2003-03-18 2012-02-29 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト セリンプロテアーゼを含むｇｌａ−残基の生産方法
AU2004221761B2 (en) * 2003-03-20 2010-01-07 Bayer Healthcare Llc FVII or FVIIa variants
US7897734B2 (en) 2003-03-26 2011-03-01 Novo Nordisk Healthcare Ag Method for the production of proteins
EP1615945B1 (de) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylierungsverfahren und durch die verfahren hergestellte proteine/peptide
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
BRPI0409936A (pt) * 2003-05-23 2006-04-25 Novo Nordisk Healthcare Ag uso de um material, recipiente pelo menos parcialmente cheio, e, kit médico
DE602004025576D1 (de) * 2003-06-19 2010-04-01 Bayer Healthcare Llc Varianten der faktor-vii- oder -viia-gla-domäne
ATE547114T1 (de) * 2003-06-25 2012-03-15 Novo Nordisk Healthcare Ag Flüssige zusammensetzungen von factor vii polypeptiden
WO2005000906A1 (ja) * 2003-06-30 2005-01-06 Otsuka Chemical Co., Ltd. ジシアロウンデカ糖鎖アスパラギン−脂肪酸アミド、これを含む医薬
DE602004023848D1 (de) * 2003-07-01 2009-12-10 Novo Nordisk Healthcare Ag Von factor vii polypeptiden
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
WO2005016365A2 (en) * 2003-08-14 2005-02-24 Novo Nordisk Health Care Ag Liquid, aqueous pharmaceutical composition of factor vii polypeptides
ATE547519T1 (de) 2003-09-09 2012-03-15 Novo Nordisk Healthcare Ag Gerinnungsfaktor-vii-polypeptide
EP2380985B1 (de) 2003-09-23 2014-01-01 University of North Carolina at Chapel Hill Vitamin-K-Epoxid-Reduktase exprimierende Zellen und deren Verwendung
WO2005035748A1 (en) 2003-10-10 2005-04-21 Novo Nordisk Health Care Ag Method for large-scale production of a polypeptide in eukaryote cells and a culture vessel suitable therefor
DE602004026897D1 (de) * 2003-10-14 2010-06-10 Baxter Healthcare Sa Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
GB0324044D0 (en) * 2003-10-14 2003-11-19 Astrazeneca Ab Protein
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
EP1711513B1 (de) 2003-12-01 2014-07-02 Novo Nordisk Health Care AG Nanofiltration von faktor vii lösungen zur entfernung von viren
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
ES2676644T3 (es) * 2003-12-19 2018-07-23 Novo Nordisk Health Care Ag Composiciones estabilizadas de polipéptidos de factor VII
WO2005068620A1 (en) * 2004-01-07 2005-07-28 Novo Nordisk Health Care Ag Method for the production of recombinant proteins
EP1745141B2 (de) 2004-05-04 2019-09-25 Novo Nordisk Health Care AG O-verknüpfte glykoformen von faktor vii und verfahren zu deren herstellung
MX2007001294A (es) * 2004-08-17 2008-03-04 Zlb Behring Gmbh Polipeptidos modificados que dependen de vitamina k.
WO2006035060A2 (en) * 2004-09-29 2006-04-06 Novo Nordisk Health Care Ag Purification of a bulk of a factor vii polypeptide by fractionated elution from an anion-exchange material
EP1814573B1 (de) 2004-10-29 2016-03-09 ratiopharm GmbH Remodellierung und glykopegylierung von fibroblasten-wachstumsfaktor (fgf)
JP2008523837A (ja) * 2004-12-21 2008-07-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト ガンマ―カルボキシル化に欠陥のある宿主系におけるガンマ―カルボキシル化ポリペプチドの発現
CN101098883B (zh) * 2004-12-23 2013-01-23 诺和诺德医疗保健公司 减少含有目的维生素k依赖性蛋白质的组合物中的蛋白质污染物的含量
CA2593682C (en) 2005-01-10 2016-03-22 Neose Technologies, Inc. Glycopegylated granulocyte colony stimulating factor
US8530192B2 (en) 2005-02-11 2013-09-10 Novo Nordisk Healthcare Ag Production of a polypeptide in a serum-free cell culture liquid containing plant protein hydrolysate
PL1853700T3 (pl) 2005-02-28 2013-05-31 Baxalta Inc Koekspresja przez rekombinowanie podjednostki 1 reduktazy epoksydu witaminy K w celu poprawy ekspresji białka zależnego od witaminy K
US20090325226A1 (en) 2005-03-15 2009-12-31 Stafford Darrel W Methods and Compositions for Producing Active Vitamin K-Dependent Proteins
EP1871795A4 (de) 2005-04-08 2010-03-31 Biogenerix Ag Zusammensetzungen und verfahren zur herstellung von glycosylierungsmutanten eines proteaseresistenten menschlichen wachstumshormons
EP1874928A1 (de) * 2005-04-13 2008-01-09 AstraZeneca AB Wirtszelle mit vektor zur herstellung von gamma-carboxylierung benötigenden proteinen
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
PL1969127T5 (pl) * 2005-12-21 2018-02-28 Cnj Holdings, Inc Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji
EP1816201A1 (de) 2006-02-06 2007-08-08 CSL Behring GmbH Modifizierter Koagulationsfaktor VIIa mit verbesserter 'half-life'-Stabiltät
WO2007104317A1 (en) 2006-03-16 2007-09-20 Drugrecure Aps Methods for local treatment with factor vii
DK2007885T3 (da) * 2006-04-11 2010-11-08 Csl Behring Gmbh Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider
FR2901707B1 (fr) 2006-05-31 2017-09-29 Lab Francais Du Fractionnement Composition de facteur vii recombinant ou transgenique, chaque molecule de facteur vii possedant deux sites de n-glycosylation a motifs glycanniques definis
JP5122562B2 (ja) * 2006-07-17 2013-01-16 ノボ ノルディスク ヘルス ケア アーゲー 増加した活性を有する第ｖｉｉａ因子アナログの新規用途
US9187532B2 (en) 2006-07-21 2015-11-17 Novo Nordisk A/S Glycosylation of peptides via O-linked glycosylation sequences
FR2904558B1 (fr) * 2006-08-01 2008-10-17 Lab Francais Du Fractionnement "composition de facteur vii recombinant ou transgenique, presentant majoritairement des formes glycanniques biantennees, bisialylees et non fucosylees"
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
JP5167449B2 (ja) * 2006-11-07 2013-03-21 独立行政法人科学技術振興機構 直鎖状核酸分子懸架支持体、直鎖状核酸分子伸長方法および直鎖状核酸分子標本
PT2101821E (pt) * 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
US8754194B2 (en) 2006-12-22 2014-06-17 Csl Behring Gmbh Modified coagulation factors with prolonged in vivo half-life
WO2008081024A1 (en) * 2007-01-03 2008-07-10 Novo Nordisk Health Care Ag Subcutaneous administration of coagulation factor viia-related popypeptdes
CN101796063B (zh) 2007-04-03 2017-03-22 拉蒂奥法姆有限责任公司 使用糖聚乙二醇化g‑csf的治疗方法
WO2008127702A2 (en) * 2007-04-13 2008-10-23 Catalyst Biosciences, Inc. Modified factor vii polypetides and uses thereof
AU2016238889B2 (en) * 2007-04-26 2019-06-27 Aptevo Biotherapeutics Llc Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
AU2008245524A1 (en) * 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
AU2014202989B2 (en) * 2007-04-26 2016-07-07 Aptevo Biotherapeutics Llc Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
WO2008154639A2 (en) 2007-06-12 2008-12-18 Neose Technologies, Inc. Improved process for the production of nucleotide sugars
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
EP2014299A1 (de) * 2007-07-11 2009-01-14 Novo Nordisk A/S Subkutane Verabreichung des Gerinnungsfaktors VII
US11197916B2 (en) 2007-12-28 2021-12-14 Takeda Pharmaceutical Company Limited Lyophilized recombinant VWF formulations
TW201731488A (zh) 2007-12-28 2017-09-16 巴克斯歐塔公司 重組ｖｗｆ調配物
CN103497247A (zh) 2008-02-27 2014-01-08 诺沃—诺迪斯克有限公司 缀合的因子viii分子
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
HRP20130414T1 (en) 2008-10-21 2013-06-30 Baxter International Inc. Lyophilized recombinant vwf formulations
US20100120093A1 (en) * 2008-11-12 2010-05-13 Baxter International Inc. Method of Producing Serum-Free Insulin-Free Factor VII
JP5027106B2 (ja) * 2008-12-25 2012-09-19 一般財団法人阪大微生物病研究会 日本脳炎ウイルス抗原
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
SG178051A1 (en) 2009-07-27 2012-03-29 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
JP5851410B2 (ja) * 2009-10-30 2016-02-03 シーエヌジェイ ホールディングス、インク． 組換えビタミンｋ依存性タンパク質の生成法
WO2011069056A2 (en) * 2009-12-04 2011-06-09 Momenta Pharmaceuticals, Inc. Antennary fucosylation in glycoproteins from cho cells
FR2954349A1 (fr) 2009-12-22 2011-06-24 Agronomique Inst Nat Rech Sulfatase modifiant selectivement les glycosaminoglycanes
WO2012075138A1 (en) * 2010-11-30 2012-06-07 Progenetics Llc Method of producing biologically active vitamin k dependent proteins in transgenic animals
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
DK2654794T3 (da) 2010-12-22 2020-06-08 Baxalta GmbH Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
EP2702077A2 (de) 2011-04-27 2014-03-05 AbbVie Inc. Verfahren zur steuerung des galactosylierungsprofil von rekombinant exprimierten proteinen
US9505833B2 (en) 2012-04-20 2016-11-29 Abbvie Inc. Human antibodies that bind human TNF-alpha and methods of preparing the same
US9334319B2 (en) 2012-04-20 2016-05-10 Abbvie Inc. Low acidic species compositions
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
EP2906236A1 (de) 2012-10-10 2015-08-19 Novo Nordisk Health Care AG Flüssige pharmazeutische zusammensetzung aus faktor-vii-polypeptiden
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
FR3006591B1 (fr) 2013-06-11 2016-05-06 Lab Francais Du Fractionnement Composition de facteur vii presentant un point isoelectrique substantiellement homogene
WO2015051293A2 (en) 2013-10-04 2015-04-09 Abbvie, Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
US10844345B2 (en) * 2014-04-16 2020-11-24 Cmc Biologics A/S High density fill and draw fermentation process
CN106687575B (zh) 2014-06-04 2021-04-30 美国安进公司 用于收获哺乳动物细胞培养物的方法
US9714302B2 (en) 2014-10-10 2017-07-25 W. R. Grace & Co.—Conn. Process for preparing spherical polymerization catalyst components for use in olefin polymerizations
FR3034669B1 (fr) 2015-04-07 2020-02-14 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Nouvelle utilisation du facteur von willebrand
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
AR105669A1 (es) * 2015-08-10 2017-10-25 Glycotope Gmbh Factor vii recombinante mejorado
AU2016363789B2 (en) 2015-12-02 2022-06-02 CSL Behring Lengnau AG Improved media for the expression of recombinant vitamin K-dependent proteins
EP3488858A1 (de) 2017-11-27 2019-05-29 Laboratoire Français du Fractionnement et des Biotechnologies Eine von-willebrand-faktor-zusammensetzung und deren verwendung zur behandlung einer durch angiogenese verursachte krankheit
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
CN117434281B (zh) * 2023-10-18 2026-01-06 上海太阳生物技术有限公司 组合物、检测试剂、检测试剂盒以及在制备检测凝血因子x活性中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189534A (en) * 1976-11-11 1980-02-19 Massachusetts Institute Of Technology Cell culture microcarriers
US4357422A (en) * 1980-08-14 1982-11-02 Massachusetts Institute Of Technology Method of enhancing interferon production
US4335215A (en) * 1980-08-27 1982-06-15 Monsanto Company Method of growing anchorage-dependent cells
US4456591A (en) 1981-06-25 1984-06-26 Baxter Travenol Laboratories, Inc. Therapeutic method for activating factor VII
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4664912A (en) * 1984-10-01 1987-05-12 Wiktor Tadeusz J Process for the large scale production of rabies vaccine
US4978616A (en) * 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4975282A (en) 1985-06-26 1990-12-04 The Liposome Company, Inc. Multilamellar liposomes having improved trapping efficiencies
SE464816B (sv) * 1985-10-15 1991-06-17 Nilsson Kjell Makroporoesa partiklar, foerfarande foer dess framstaellning och dess anvaendning
US4783940A (en) 1985-12-28 1988-11-15 Shimizu Construction Co., Ltd. Concrete filled steel tube column and method of constructing same
US5595886A (en) * 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5576194A (en) * 1986-07-11 1996-11-19 Bayer Corporation Recombinant protein production
JPH01502080A (ja) * 1986-11-17 1989-07-27 ニュー・イングランド・メディカル・センター 組み換えビタミンｋ依存性蛋白質のガンマカルボキシル化の増強
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5580560A (en) * 1989-11-13 1996-12-03 Novo Nordisk A/S Modified factor VII/VIIa
CA2087970A1 (en) * 1990-07-23 1992-01-24 Kathleen L. Berkner Gamma-carboxylase and methods of use
EP0785273A1 (de) * 1990-11-26 1997-07-23 Genetics Institute, Inc. Gepaarte basische Aminosäuren konvertierendes Enzym und dafür kodierende DNA Sequenz
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
JP3459416B2 (ja) * 1991-02-28 2003-10-20 ザイモジェネティクス，インコーポレイティド 修飾されたファクター▲ｖｉｉ▼
US5661008A (en) * 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5268275A (en) * 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
US5733761A (en) 1991-11-05 1998-03-31 Transkaryotic Therapies, Inc. Protein production and protein delivery
IL104385A (en) * 1992-01-17 1995-12-31 Applied Research Systems Method and device for growing biomass particles
DK53792D0 (da) * 1992-04-24 1992-04-24 Novo Nordisk As Fremgangsmaade til fremstilling af proteiner
EP0592692B1 (de) * 1992-05-01 1997-07-02 Teijin Limited Fed-batch-Verfahren für Proteine sekretierende Zellen
DE4221863C2 (de) 1992-07-03 1997-04-17 Stockhausen Chem Fab Gmbh Copolymere der Allyliminodiessigsäure mit ungesättigten Carbonsäuren und deren Verwendung als Komplexbildner, Peroxidstabilisatoren, Builder in Wasch- und Reinigungsmitteln und Dispergatoren
US5510328A (en) * 1994-04-28 1996-04-23 La Jolla Cancer Research Foundation Compositions that inhibit wound contraction and methods of using same
WO1998004680A1 (en) * 1996-07-26 1998-02-05 University Of Manitoba Serum-free medium for growth of anchorage-dependant mammalian cells
BR9807936A (pt) * 1997-04-08 2000-02-22 Baxter Ag Preparação farmacêutica imuno-tolerante de complexo de pró-trombina, processo para a produção de uma preparação, e, utilização de uma preparação
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AT407255B (de) * 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
JP4463988B2 (ja) * 1998-11-06 2010-05-19 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト Ｖｉｉ因子の生産方法
AU3629800A (en) 1999-03-16 2000-10-04 Children's Hospital Of Philadelphia, The Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors
AU780810B2 (en) 1999-08-05 2005-04-21 Baxalta GmbH Recombinant stable cell clone, its production and use thereof
UA74557C2 (en) * 1999-09-03 2006-01-16 Applied Research Systems A method for producing a heterologous secreted protein from chinese hamster ovaries cells grown on microcarriers
BR0110248A (pt) * 2000-04-26 2003-01-07 Aventis Pharma Gmbh Receptor de edg8, sua preparação e uso

Also Published As

Publication number Publication date
US20020151471A1 (en) 2002-10-17
HUP0301267A3 (en) 2005-12-28
CN102766668A (zh) 2012-11-07
US20050075289A1 (en) 2005-04-07
CZ2003718A3 (cs) 2003-08-13
EP2311943A2 (de) 2011-04-20
JP2004510786A (ja) 2004-04-08
ATE425254T1 (de) 2009-03-15
DE60141908D1 (de) 2010-06-02
EP2311943A3 (de) 2011-05-04
PL361017A1 (en) 2004-09-20
AU2001291651A1 (en) 2002-04-15
KR100861470B1 (ko) 2008-10-02
WO2002029045A3 (en) 2002-10-10
US20090281022A1 (en) 2009-11-12
WO2002029083A3 (en) 2003-08-21
JP4477299B2 (ja) 2010-06-09
AU2001291653A1 (en) 2002-04-15
NO20031471L (no) 2003-05-30
US6903069B2 (en) 2005-06-07
JP2004510436A (ja) 2004-04-08
IL154880A0 (en) 2003-10-31
JP2004512835A (ja) 2004-04-30
PL361058A1 (en) 2004-09-20
CN102766668B (zh) 2016-03-16
MXPA03002853A (es) 2005-05-16
BR0114373A (pt) 2004-02-17
WO2002029045A2 (en) 2002-04-11
WO2002029084A3 (en) 2002-09-26
BR0114374A (pt) 2003-12-30
JP2004510439A (ja) 2004-04-08
US20070122884A1 (en) 2007-05-31
CA2422214A1 (en) 2002-04-11
CA2422216C (en) 2010-03-16
EP1325127A2 (de) 2003-07-09
CN1468303A (zh) 2004-01-14
ES2344887T3 (es) 2010-09-09
CN1481438A (zh) 2004-03-10
AU9165201A (en) 2002-04-15
WO2002029083A2 (en) 2002-04-11
CA2422216A1 (en) 2002-04-11
WO2002029025A3 (en) 2002-10-10
US20040058413A1 (en) 2004-03-25
NO20031471D0 (no) 2003-04-01
WO2002029025A2 (en) 2002-04-11
EP1325113B1 (de) 2010-04-21
AU2001295431A1 (en) 2002-04-15
IL154879A0 (en) 2003-10-31
WO2002029025A9 (en) 2003-05-15
AU2001291652B2 (en) 2007-09-13
KR20030034245A (ko) 2003-05-01
HUP0301267A2 (hu) 2003-09-29
US8202973B2 (en) 2012-06-19
KR20030081310A (ko) 2003-10-17
HUP0301245A2 (hu) 2003-09-29
ES2323761T3 (es) 2009-07-24
JP4361730B2 (ja) 2009-11-11
EP1356074A2 (de) 2003-10-29
DE60137950D1 (de) 2009-04-23
WO2002029084A2 (en) 2002-04-11
HUP0301245A3 (en) 2005-12-28
EP2261330A1 (de) 2010-12-15
US20020137673A1 (en) 2002-09-26
KR100880624B1 (ko) 2009-01-30
EP1325127B1 (de) 2009-03-11
EP1325113A2 (de) 2003-07-09
CN1468303B (zh) 2012-07-18
EP1325147A2 (de) 2003-07-09

Similar Documents

Publication Publication Date Title
ATE465253T1 (de) Glykoformen von faktor vii
DE60108780D1 (de) Automatische erzeugung von mustern
ATE321146T1 (de) Methoden zur modifikation von kohlenhydratanteilen
DE60136181D1 (de) 3'-prodrugs von 2'-deoxy-beta-l-nukleosiden
DE60222326D1 (de) Verfahren zur Herstellung von bioabbaubaren Fasern
DE60126266D1 (de) Verfahren zur oligomerisierung von alkenen
DE60221457D1 (de) System für die Bleiche von verfärbten Zähnen
DE60127602D1 (de) Verfahren zur Herstellung von Halbleiterchips
DE69829888D1 (de) Verfahren zur Herstellung von Hydroperoxiden
DE50106427D1 (de) Verfahren zur Herstellung von Alkalimetall- und Ammoniumperoxidsulfat
DE69919049D1 (de) Herstellung von gefällten Kalziumkarbonatenthaltenden Produkten
DE60121522D1 (de) Verfahren zur Herstellung von Ethylencopolymeren und die erhaltenen Ethylenecopolymere
DE69900514D1 (de) Herstellung von Polyalkylsilsesquioxan-Partikeln
DE69208387D1 (de) Herstellung von feuchtigkeitshärtenden Organosiloxanzusammensetzungen
DE69108740D1 (de) Herstellung von peroxidzusammensetzungen.
DE69515671D1 (de) Bestimmung der biodegradabilität von asparaginsäurederivaten, abbaubare chelatbildner, verwendungen und zusammensetzungen davon
DE60138418D1 (de) Verfahren zur herstellung von ethylenhomopolymeren und copolymeren
ATE492682T1 (de) Verfahren und wässerige zusammensetzung zur herstellung von verbessertem zellstoff
DE69920003D1 (de) Verfahren zur herstellung von 1,3-disubstituierten-4-oxocyclischen harnstoffen
DE60107191D1 (de) Herstellung von 2-Hydrocarbyl-2-Adamantylacrylaten
DE69901637D1 (de) Herstellung von korrosiosbeständigen keramischen Bauteilen
DE60200524D1 (de) Reaktor zur Herstellung von Feuchtigkeit
ITMI20011833A0 (it) Agenti che regolano la permeabilita' vascolare
DE10291136D2 (de) Verfahren zur Herstellung von adaptronischen Mikrosystemen
EP1334166A4 (de) Herstellung von destillaten mit niedrigem schwefelgehalt

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1325113

Country of ref document: EP